Evidence map›Paper›PMID 34596427›Full record

ArticleAIDS education and prevention : official publication of the International Society for AIDS Education2021

Acceptability of a Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults (MTN-033 Study).

José A Bauermeister, Ryan C Tingler, Sherri Johnson, Nicole Macagna, Jonathan Lucas, Clara Dominguez-Islas, Daniel Szydlo, Julie Ngo, Cindy E Jacobson, Lindsay Kramzer and 8 more

Abstract read
In one paragraph

Article in AIDS education and prevention : official publication of the International Society for AIDS Education, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Acceptability of PC-1005 Gel Administered Rectally to HIV-1 Seronegative Adults at Three Different Volume Levels (MTN-037).AIDS education and prevention : official publication of the International Society for AIDS Education · 2022
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

José A BauermeisterUniversity of Pennsylvania, Philadelphia, Pennsylvania.
Ryan C TinglerUniversity of Pennsylvania, Philadelphia, Pennsylvania.
Sherri JohnsonFHI 360, Durham, North Carolina.
Nicole MacagnaFHI 360, Durham, North Carolina.
Jonathan LucasFHI 360, Durham, North Carolina.
Clara Dominguez-IslasFred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, Washington.
Daniel SzydloStatistical Center for HIV/AIDS Research & Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Julie NgoStatistical Center for HIV/AIDS Research & Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Cindy E JacobsonUniversity of Pittsburgh, Pittsburgh, Pennsylvania.
Lindsay KramzerUniversity of Pittsburgh, Pittsburgh, Pennsylvania.
Devika SinghUniversity of Pittsburgh, Pittsburgh, Pennsylvania.
Charlene S DezzuttiUniversity of Pittsburgh, Pittsburgh, Pennsylvania.
Ratiya Pamela Kunjara Na AyudhyaUniversity of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania.
Jeanna PiperDivision of AIDS/NIAID/NIH, Bethesda, Maryland.
Bríd DevlinInternational Partnership for Microbicides, Silver Spring, Maryland.
Craig W HendrixMicrobicide Trials Network, Pittsburgh, Pennsylvania.
Ken HoUniversity of Pittsburgh, Pittsburgh, Pennsylvania.
MTN-033 Protocol Team

Funding

Microbicide Trials NetworkUM1AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2011 to 2021
$175.0M
Statistical and Data Management Center (SDMC): Microbicide Trials NetworkUM1AI068615 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BROWN, ELIZABETH RENATA · 2011 to 2021
$66.5M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Alan David Levine · 1994 to 2026
$50.0M
Laboratory Center (LC): Microbicide Trials NetworkUM1AI106707 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI MELLORS, JOHN W, ROHAN, LISA CENCIA · 2014 to 2021
$27.1M
NIAID NIH HHS P30 AI036219NIAID NIH HHS UM1 AI068615NIAID NIH HHS UM1 AI068633NIAID NIH HHS UM1 AI106707
6 · The paper itself

Abstract

We triangulated quantitative and qualitative assessments to evaluate participants' acceptability of 0.05% dapivirine rectal microbicide (RM) gel administered via two separate modalities (a rectal applicator and an artificial phallus for use as a coital simulation device) as part of a Phase I trial (N = 14) among men who have sex with men (MSM) randomized using a 1:1 ratio. Overall, participants reported favorable acceptability of the gel (n = 11; 78.6%), the same or more at the end of the study compared to when they started the study. Additionally, when discussing their preferred administration modality, they noted that both methods had positive qualities but also potential areas of improvement. Our findings underscore the need to create multiple delivery methods for a future microbicide gel (i.e., with and without the need for an applicator) and highlight the importance of offering MSM choices in how biomedical HIV prevention strategies are delivered.

Indexed as

HIV-1HIV InfectionsSexual and Gender MinoritiesAdministration, RectalAdultHomosexuality, MaleHumansMalePyrimidinesDapivirinePyrimidinesbehavioral congruenceHIVHIV preventionmicrobicidesrectal

Identifiers

PMID34596427
PMCPMC8637489

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.